Neuroprotective Small Molecules for the Treatment of Amyotrophic Lateral Sclerosis
Abstract
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease for which there is no cure. Because of the lack of understanding of the cause of ALS, treatment is limited to mechanical intervention and riluzole, both of which extend existence rather than extend life. Thus, there is an urgent need to find drugs that are of some benefit to ALS. To this end, we are developing a cell-based co-culture high throughput screening system which is composed of mutant SOD1 astrocyte-conditioned medium (ACM), ES-MNs and a high-throughput screening robot, that we believe, will give faster screening of chemicals and drugs to treat ALS. We have, thus far, validated our co-culture system, validated that our high throughput screening technique works and miniaturized our system to a 96 well plate. Z?-factor (between 0.5-1.0) is a measure of how good an assay is. At present, our Z?-factor is 0.3, and we are working on improving this value. Nonetheless, we have identified 108 compounds, from our first screen from chemical libraries, that have a wide range of actions. Of these 108 compounds, five have reached the second screen stage and two of the five hold good possibilities. With our system, we noted that JNK2/3 inhibitors are protective for primary motor neurons and ES-MNs) which was confirmed on a low throughput screen. Compared to other high throughput screening systems, our readout is simple: survival of ES-MNs in ACM treated with one of the hits from our high throughput screen coculture system seems to be successful in finding small molecules that are possibilities for the treatment of ALS.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 30, 2012
- Accession Number
- ADA567841
Entities
People
- Serge Przedborski
Organizations
- Columbia University